[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345879-105":59,"doc-detail-345879-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","selected-chemokines-as-prognostic-biomarkers-and-therapeutic-targets-in-ovarian-cancer","Selected Chemokines as Prognostic Biomarkers and Therapeutic Targets in Ovarian Cancer","","Ovarian cancer, especially high-grade serous ovarian cancer (HGSOC), remains highly lethal due to delayed detection and the emergence of chemoresistance. The tumor microenvironment (TME) drives progression, and chemokines shape multiple processes including cell recruitment, angiogenesis, metastasis, and immune modulation. This review consolidates evidence on major chemokine axes with dual relevance as prognostic biomarkers and therapeutic targets. It highlights CXCL12/CXCR4, CCL2/CCR2, and CCL5/CCR5, contrasts pro-angiogenic ELR+CXC and effector chemokines associated with improved outcomes, and summarizes preclinical inhibitor strategies such as plerixafor, PF-04136309, and maraviroc.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/selected-chemokines-as-prognostic-biomarkers-and-therapeutic-targets-in-ovarian-cancer/345879/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/selected-chemokines-as-prognostic-biomarkers-and-therapeutic-targets-in-ovarian-cancer/345879.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are chemokines important in ovarian cancer progression?","Question",{"text":112,"@type":113},"Chemokines act as low-molecular-weight chemotactic cytokines that regulate immune-cell recruitment and distribution within tumors. They also influence interactions that can either support antitumor responses or promote immune escape.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which chemokine axes are highlighted as prognostic biomarkers and therapeutic targets?",{"text":117,"@type":113},"The review focuses on CXCL12/CXCR4, CCL2/CCR2, and CCL5/CCR5. These axes are linked to tumor proliferation, angiogenesis, chemoresistance, immunosuppressive microenvironments, and Treg/MDSC infiltration.",{"name":119,"@type":110,"acceptedAnswer":120},"How do different chemokine profiles relate to outcomes and therapy response?",{"text":121,"@type":113},"High expression of immunosuppressive chemokines is associated with poorer prognosis and therapy resistance. In contrast, effector chemokines correlated with “hot” immune subtypes are linked to improved survival and better chemotherapy responsiveness.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},345879,1790399875,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Review  \nSelected Chemokines as Prognostic Biomarkers and Therapeutic Targets in Ovarian Cancer  \nAnna Długaszek 1,2, *, Jacek Kabut 1,2, Małgorzata Domagała-Haduch 1,2, Anita Gorzelak-Magiera 1,2, Joanna Sadurska 2, Maria-Laura Morawiec 3, Aleksandra Mielczarek-Palacz 3  \nand Iwona Gisterek-Grocholska 1,2  \nAcademic Editor: Stergios Boussios  \nReceived: 6 May 2026  \nRevised: 8 June 2026  \nAccepted: 17 June 2026  \nPublished: 30 June 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Oncology and Radiotherapy, Medical University of Silesia, 40-055 Katowice, Poland  \n2 Clinical Oncology Unit, The Professor K. Gibi ´nski University Clinical Center of the Silesian Medical, Medical University of Silesia, 40-055 Katowice, Poland  \n3 Department of Immunology and Serology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland  \n* Correspondence: [aniakrywult@gmail.com](aniakrywult@gmail.com)  \nAbstract  \nOvarian cancer, particularly high-grade serous ovarian cancer (HGSOC), remains one of the most lethal gynecological malignancies due to late diagnosis and the development of chemoresistance. The tumor microenvironment (TME) plays an important role in disease progression, with chemokines influencing cell recruitment, angiogenesis, metastasis, and immune modification. This review synthesizes current evidence on key chemokine axes in ovarian cancer, highlighting their dual roles as prognostic biomarkers and therapeutic targets. The most important axes include CXCL12/CXCR4 (which drives tumor proliferation, angiogenesis and chemoresistance via epithelial–mesenchymal transition), CCL2/CCR2 (promoting immunosuppressive tumor-associated macrophages and resistance), and CCL5/CCR5 (enhancing pro-oncogenic signaling and Treg/MDSC infiltration) . Pro-angiogenic ELR+CXC chemokines like CXCL8 induce vascularization and inflammation. On the contrary, effector chemokines (CXCL9/10/11/13) correlate with “hot”immune subtypes and improved survival in several studies. High expression of immunosuppressive chemokines predicts poorer prognosis and therapy resistance, while immune-attracting profiles associate with better outcomes and chemotherapy responsiveness. Therapeutically, inhibitors like plerixafor (CXCR4), PF-04136309 (CCR2), and maraviroc (CCR5) show preclinical promise, synergizing with chemotherapy, anti-VEGF, and checkpoint inhibitors. Chemokines also represent actionable molecular targets to overcome ovarian cancer’s “cold” immune phenotype. Future research should validate multi-chemokine signatures for patient stratification and advanced clinical trials toward personalized therapies.  \nKeywords: ovarian cancer; chemokines; tumor microenvironment; chemoresistance  \n1. Introduction  \nOvarian cancer is one of the most lethal gynecological cancers [1] . Due to its late diagnosis, most patients are diagnosed at an advanced stage (FIGO stage III–IV) . Despite significant advances in treatment in recent years, fewer than half of patients survive 5 years after diagnosis, and ovarian cancer is still considered a chronic disease with alternating periods of remission and relapse [2] . The predominant histological type is high-grade serous ovarian cancer (HGSOC), which is characterized by an  \naggressive course and a high tendency to recur. Standard therapy is cytoreductive surgery and platinum-based chemotherapy [3] . Depending on the molecular profile of the tumor and the response to treatment, therapy is supplemented with bevacizumab and/or PARP (ADP-ribose polymerase) inhibitors. One of the priorities remains the search for new therapeutic targets, biomarkers of treatment resistance, and attempts to personalize therapy.  \nIn recent years, researchers have focused on the tumor microenvironment and the role of the immune system ","cbCaif45wxdmpG98","https://ap.wps.com/l/cbCaif45wxdmpG98","pdf",1095988,18,"English","# Abstract\n# 1. Introduction\n# 2. Chemokines in the Ovarian Tumor Microenvironment Have Potential as Therapeutic Targets","[{\"question\":\"Why are chemokines important in ovarian cancer progression?\",\"answer\":\"Chemokines act as low-molecular-weight chemotactic cytokines that regulate immune-cell recruitment and distribution within tumors. They also influence interactions that can either support antitumor responses or promote immune escape.\"},{\"question\":\"Which chemokine axes are highlighted as prognostic biomarkers and therapeutic targets?\",\"answer\":\"The review focuses on CXCL12/CXCR4, CCL2/CCR2, and CCL5/CCR5. These axes are linked to tumor proliferation, angiogenesis, chemoresistance, immunosuppressive microenvironments, and Treg/MDSC infiltration.\"},{\"question\":\"How do different chemokine profiles relate to outcomes and therapy response?\",\"answer\":\"High expression of immunosuppressive chemokines is associated with poorer prognosis and therapy resistance. In contrast, effector chemokines correlated with “hot” immune subtypes are linked to improved survival and better chemotherapy responsiveness.\"}]","Selected Chemokines as Prognostic Biomarkers and Therapeutic Targets in Ovarian Cancer | PDF",1790059218,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d72746f7622c81985fff0166627090a6.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9978c82eab0bdacfc85460237efc301e.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b818973e02b9db1e16dab3fdafb8b99e.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f3892ab27351658b8c7394af1d73e4b.webp",980,1385]